Henk, Henry J <br/><br/>
Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.  [electronic resource] 

 -  American journal of hematology  May 2012 
 - 490-5 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-8652 
<br/><br/><label>Standard No.: </label>10.1002/ajh.23164  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Bone Density Conservation Agents--administration & dosage<br/>Databases, Factual<br/>Diphosphonates--administration & dosage<br/>Drug Utilization<br/>Female<br/>Fractures, Spontaneous--epidemiology<br/>Humans<br/>Imidazoles--administration & dosage<br/>Incidence<br/>Infusions, Intravenous<br/>International Classification of Diseases<br/>Male<br/>Medication Adherence<br/>Middle Aged<br/>Multiple Myeloma--complications<br/>Osteolysis--epidemiology<br/>Retrospective Studies<br/>Treatment Outcome<br/>United States--epidemiology<br/>Zoledronic Acid